Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study

The incidence of hepatitis C virus (HCV) infection is much higher in hemodialysis patients than that in healthy individuals. The prognosis of hemodialysis patients with HCV infection is poorer than that without HCV infection. Therefore, antiviral intervention is pivotal for HCV infection in hemodialysis patients. Recent evaluations of the pangenotypic regimen of glecaprevir/pibrentasvir show that it is highly effective and safe for HCV‐infected hemodialysis patients. However, a few reports showed that the effect of HCV elimination by glecaprevir/pibrentasvir improved liver dysfunction or anemia. The aim of the present study was to determine clinical outcomes after HCV elimination using the glecaprevir/pibrentasvir regimen in HCV‐infected hemodialysis patients.

[1]  N. Hotta,et al.  The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study , 2019, Alimentary pharmacology & therapeutics.

[2]  M. Kurosaki,et al.  Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection , 2019, Journal of Gastroenterology.

[3]  N. Sakamoto,et al.  The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment , 2018, Internal medicine.

[4]  A. Tsubota,et al.  Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study , 2018, Journal of gastroenterology and hepatology.

[5]  A. Tsubota,et al.  Epidemiological Survey of Patients With Hemodialysis Complicated by Hepatitis C in Japan , 2018, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  A. Tsubota,et al.  Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  B. Bacon,et al.  Real‐world use of elbasvir‐grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network , 2018, Alimentary pharmacology & therapeutics.

[8]  T. Hasegawa,et al.  International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[9]  A. Tsubota,et al.  Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  K. Chayama,et al.  Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection , 2017, Hepatology.

[11]  N. Enomoto,et al.  Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection , 2017, Journal of Gastroenterology.

[12]  S. Pol,et al.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment , 2017, The New England journal of medicine.

[13]  A. Tsubota,et al.  Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  H. Yoshiji,et al.  Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis , 2017, Journal of Gastroenterology.

[15]  A. Tsubota,et al.  Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[16]  M. Imamura,et al.  The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy , 2017, PloS one.

[17]  S. Pol,et al.  Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. , 2017, The lancet. Gastroenterology & hepatology.

[18]  M. Londoño,et al.  Treating Hepatitis C in Patients with Renal Failure , 2017, Digestive Diseases.

[19]  S. Kottilil,et al.  Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection , 2017, Hepatology International.

[20]  M. Jadoul,et al.  Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[21]  H. Ohdan,et al.  Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study , 2016, Journal of viral hepatitis.

[22]  P. Messa,et al.  New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. , 2016, Kidney international.

[23]  T. Ishikawa,et al.  Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis , 2016, Journal of Gastroenterology.

[24]  N. Hayashi,et al.  JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2 , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  F. Sato,et al.  Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C , 2016, Journal of Gastroenterology.

[26]  K. Chayama,et al.  Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis , 2015, Hepatology.

[27]  T. Ide,et al.  Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. , 2015, The Lancet. Infectious diseases.

[28]  T. Ide,et al.  Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial , 2014, Journal of viral hepatitis.

[29]  C. Hsiao,et al.  Age and gender differences in the relationship between hepatitis C infection and all stages of Chronic kidney disease , 2014, Journal of viral hepatitis.

[30]  Yu-Chieh Su,et al.  A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. , 2014, Kidney international.

[31]  K. Chayama,et al.  Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection , 2014, Hepatology.

[32]  M. Jadoul,et al.  Hepatitis C Infection Is Very Rarely Treated among Hemodialysis Patients , 2013, American Journal of Nephrology.

[33]  N. Izumi,et al.  2011 Japanese Society for Dialysis Therapy Guidelines for the Treatment of Hepatitis C Virus Infection in Dialysis Patients , 2012, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[34]  S. Weisbord,et al.  Health-related quality of life outcomes in chronic kidney disease , 2010, Current opinion in nephrology and hypertension.

[35]  A. Macleod.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. , 2008, Kidney international. Supplement.

[36]  K. Nitta,et al.  Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan , 2008, Clinical and Experimental Nephrology.

[37]  S. Greenland,et al.  Hepatitis C virus and death risk in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.

[38]  K. Akazawa,et al.  Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. , 2006, Kidney international.

[39]  F. Fabrizi,et al.  Hepatitis C infection and the patient with end‐stage renal disease , 2002, Hepatology.

[40]  M. Takasugi,et al.  Programmed filtration, a new method for removing large molecules and regulating albumin leakage during hemodiafiltration treatment. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  F. Marumo,et al.  Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. , 2000, Journal of the American Society of Nephrology : JASN.

[42]  A. Al-Khader,et al.  Influence of Hepatitis C Virus Infection upon Parenteral Iron and Erythropoietin Responsiveness in Regular Haemodialysis Patients , 2000, Nephron.

[43]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[44]  C. Schmid,et al.  Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  M. Mizokami,et al.  New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a , 1997, Journal of clinical microbiology.